Related Experiment Videos
Intravitreal triamcinolone injection for chronic diffuse diabetic macular oedema
Remzi Avci1, Berkant Kaderli, Fatma D Akalp
1Department of Ophthalmology, Uludag University Hospital, 16059 Gorukle, Bursa, Turkey. ravci@uludag.edu.tr
Clinical & Experimental Ophthalmology
|February 3, 2006
Summary
Intravitreal triamcinolone effectively reduced chronic diffuse diabetic macular edema, improving visual acuity and resolving edema in most cases. While generally safe, potential side effects like increased intraocular pressure and cataract progression require monitoring.
Area of Science:
- Ophthalmology
- Endocrinology
Background:
- Diabetic macular edema (DME) is a leading cause of vision loss in diabetic patients.
- Chronic diffuse DME poses significant therapeutic challenges.
Purpose of the Study:
- To evaluate the efficacy and safety of intravitreal triamcinolone acetonide for chronic diffuse DME.
- To assess visual acuity changes and macular edema resolution post-injection.
Main Methods:
- Prospective case series of 59 eyes with chronic diffuse DME.
- Intravitreal injection of 4 mg triamcinolone acetonide.
- Evaluation through clinical examination and fluorescein angiography, monitoring for complications.
Main Results:
- Significant improvement in mean visual acuity noted at 3 months post-injection (P < 0.01).
- Macular edema resolved or decreased in all eyes; however, recurrence was observed in 49% by 6 months.
- Elevated intraocular pressure (10 eyes) and cataract progression (4 eyes) were managed; no endophthalmitis occurred.
Conclusions:
- Intravitreal triamcinolone acetonide is a potentially effective and safe treatment for chronic diffuse DME.
- Further research is needed to determine long-term outcomes and optimal retreatment strategies.